Mira IX Acquisition Corp. (“Mira IX”) (TSXV:MIA.P) is pleased to announce that it has entered into a letter of intent dated October 6, 2017 with Nuuvera Corp. (“Nuuvera”) to complete a going-public transaction in Canada for Nuuvera (the “Proposed Transaction”). Mira IX intends that the Proposed Transaction will constitute its “Qualifying Transaction” under Policy 2.4 – Capital Pool Companies of the TSX Venture Exchange (the “TSXV”). For convenience, Mira IX, as it will exist after completion of the Proposed Transaction, is sometimes referred to herein as the “Resulting Issuer”.
Nuuvera is engaged in the testing, formulation, production, extraction and sale of medicinal cannabis products in Canada and other legal International jurisdictions (excluding the United States, where no Nuuvera business is conducted). Nuuvera carries on its business through its subsidiaries, ARA-Avanti Rx Analytics Inc. (“Avanti”), of which Nuuvera indirectly holds 51%, and Avalon Pharmaceuticals Inc. (“Avalon”), an indirect, wholly-owned subsidiary of Nuuvera.
Avanti is a “Licensed Dealer” as defined pursuant to the…
See the entire news release.